Uncertainty exists whether the use of non-prescription psychoactive substances following onset of a first episode of psychosis (FEP), in particular cannabis use, affects medication adherence. Data from FEP patients (N=233) obtained through prospective assessments measured medication adherence and pattern of cannabis and other substance use in the first two years following onset of psychosis. Multiple logistic regression analyses were employed to compare the different substance use groups with regard to risk of medication non-adherence, while controlling for confounders. The proportion of non-adherent patients was higher in those who continued using high-potency forms of cannabis (skunk-like) following the onset (83%) when compared to never regular users (51%), corresponding to an Odds Ratio (OR) of 5.26[95% Confidence Interval (CI) 1.91-15.68]. No significant increases in risk were present in those who used cannabis more sporadically or used milder forms of cannabis (hash-like). Other substances did not make an independent contribution in this model, including cigarette use ([OR 0.88, 95% CI 0.41-1.89]), alcohol use ([OR 0.66, 95% CI 0.27-1.64]) or regular use of other illicit drugs ([OR 1.03, 95% CI 0.34-3.15]) following the onset. These results suggest that continued use of high-potency cannabis following the onset of psychosis may adversely affect medication adherence.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.psychres.2017.05.009 | DOI Listing |
ACR Open Rheumatol
January 2025
Duke University and Duke Clinical Research Institute, Durham, North Carolina.
Objective: The objective of this study was to evaluate the preliminary effectiveness of an electronic pill bottle with automated reminders on hydroxychloroquine (HCQ) adherence in children with pediatric systemic lupus erythematosus (pSLE).
Methods: This was a self-controlled, open label, direct-to-family pilot trial. Children with pSLE treated with HCQ were recruited from the Childhood Arthritis and Rheumatology Research Alliance Registry.
Acta Endocrinol (Buchar)
January 2025
JSS Dental College and Hospital, JSS Academy of Higher Education and Research, Mysuru, Karnataka, India.
Introduction: Diabetes mellitus, a chronic metabolic disorder stemming from pancreatic dysfunction, is surging in India, notably among those aged 60 and above. The escalating disease prevalence in this demographic necessitates heightened medication use, escalating the risk of Adverse Drug Reactions (ADRs). This underscores the vital role of ADR monitoring to curtail potential harm.
View Article and Find Full Text PDFFront Public Health
January 2025
School of Nursing and Health Management, Shanghai University of Medicine and Health Sciences, Shanghai, China.
Introduction: This study investigated segmented assimilation patterns and factors influencing health education utilization (HEU) among internal migrant populations in China, driven by concerns over their declining health owing to urbanization-related changes.
Methods: Data from the 2017 China Migrants Dynamic Survey were analyzed, focusing on 13,998 rural migrants. Negative binomial regression was used to explore assimilation patterns and determine the factors affecting HEU among internal migrants in China.
Explor Res Clin Soc Pharm
March 2025
University of Iowa, Department of Pharmacy Practice and Science, 180 S Grand Avenue 339 CPB, Iowa City, IA 52242, United States of America.
Objectives: To implement the Cardiovascular Practice Transformation (CPT) program and evaluate its impact on blood pressure, and to assess the feasibility of implementing the CPT program by identifying obstacles and facilitators.
Methods: Twenty-three Iowa pharmacies participated in the program, each monitoring approximately 10 hypertensive patients for 6 months. Pharmacists assessed blood pressure, medication adherence and addressed medication-related problems during patient visits.
Clin Pharmacol
January 2025
Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.
Various repurposing drugs have been tested for their efficacy on coronavirus disease 2019 (COVID-19), including antimalarial drugs. During the pandemic, Chloroquine (CQ) and Hydroxychloroquine (HCQ) demonstrated good potential against COVID-19, but further studies showed both drugs had side effects that were more dangerous than the efficacy. This made World Health Organization (WHO) ban the usage for COVID-19 patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!